Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded at Wedbush

Wedbush upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from an underperform rating to a neutral rating in a report issued on Monday, Marketbeat.com reports. The firm currently has $4.00 price target on the stock. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q3 2024 earnings at ($0.86) EPS, Q4 2024 earnings at ($0.87) EPS, FY2024 earnings at ($2.83) EPS, Q1 2025 earnings at ($0.91) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($3.25) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.19) EPS and FY2028 earnings at ($1.31) EPS.

Other research analysts also recently issued research reports about the stock. Morgan Stanley restated an equal weight rating and set a $8.00 price target (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an overweight rating to an equal weight rating and cut their price objective for the stock from $29.00 to $9.00 in a research note on Tuesday, June 18th. Oppenheimer decreased their target price on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an outperform rating on the stock in a research report on Tuesday, June 18th. HC Wainwright reaffirmed a buy rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday. Finally, UBS Group downgraded Zentalis Pharmaceuticals from a buy rating to a neutral rating and reduced their price objective for the company from $28.00 to $5.00 in a research note on Thursday, June 20th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $11.33.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $3.20 on Monday. The stock has a market capitalization of $227.28 million, a PE ratio of -0.96 and a beta of 1.70. The business has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $10.12. Zentalis Pharmaceuticals has a 12 month low of $2.83 and a 12 month high of $27.79.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same period in the prior year, the firm earned ($1.85) EPS. On average, equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.72 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Cam Gallagher sold 9,597 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.98, for a total transaction of $114,972.06. Following the transaction, the chief financial officer now owns 633,680 shares in the company, valued at approximately $7,591,486.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ZNTL. Quest Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $38,000. Anfield Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at about $40,000. Tower Research Capital LLC TRC increased its position in shares of Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after acquiring an additional 2,589 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $58,000. Finally, American Century Companies Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $95,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.